


<b>PATENT APPLICATION TRANSMITTAL LETTER</b> (Large Entity)	Docket No. <b>BDI-1020</b>
--	-------------------------------



TO THE ASSISTANT COMMISSIONER FOR PATENTS

Transmitted herewith for filing under 35 U.S.C. 111 and 37 C.F.R. 1.53 is the patent application of:

**Alexander J. Ryncarz**

**For: Positive Controls in Polynucleotide Amplification**

Enclosed are:

- ☒ Certificate of Mailing with Express Mail Mailing Label No.
- ☒ 4 sheets of drawings.
- ☐ A certified copy of a \_\_\_\_\_ application.
- ☒ Declaration      ☒ Signed.      ☐ Unsigned.
- ☒ Power of Attorney
- ☐ Information Disclosure Statement
- ☐ Preliminary Amendment
- ☒ Other: Sequence Listing, Sequence Listing in Computer Readable Form, Statement under 37 CFR 1.821(f)

**CLAIMS AS FILED**

For	#Filed	#Allowed	#Extra		Rate	Fee
<b>Total Claims</b>	57	- 20 =	37	x	\$22.00	\$814.00
<b>Indep. Claims</b>	6	- 3 =	3	x	\$80.00	\$240.00
<b>Multiple Dependent Claims (check if applicable)</b> <input type="checkbox"/>						\$0.00
<b>BASIC FEE</b>						\$770.00
<b>TOTAL FILING FEE</b>						\$1,824.00

- ☐ A check in the amount of \_\_\_\_\_ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. **02-1755** as described below. A duplicate copy of this sheet is enclosed.
  - ☒ Charge the amount of **\$1,824.00** as filing fee.
  - ☒ Credit any overpayment.
  - ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
  - ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: **January 30, 1997**

\_\_\_\_\_  
 Signature  
**Barbara V. Maurer, Reg. No. 31,278**

CC:

260210-0426430

08/791240



EXPRESS MAIL#EF932413802 US  
Docket No. BDI-1020

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re U.S. Patent Application

Group:

Alexander J. Ryncarz

Examiner:

Serial Number:

Filed:

For: Positive Controls in Polynucleotide Amplification

**EXPRESS MAILING**

January 30, 1997

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Attention: Box Sequence  
Sir:

I hereby certify that the following documents:

Assignment & Assignment Transmittal Sheet;  
Combined Declaration & Power of Attorney;  
Formal Drawings;  
Postcard;  
Sequence Listing (4 pages);  
Sequence Listing in Computer Readable Format;  
Specification (101 pages);  
Transmittal Sheet; and  
Express Mailing Certificate

are being deposited in the United States Postal Service EXPRESS MAIL Label No. **EXPRESS**  
**MAIL#EF932413802 US** in an envelope addressed to: Box Sequence, Honorable Commissioner of Patents and  
Trademarks, Washington, D.C. 20231 on **January 30, 1997**.

Respectfully Submitted,

Barbara V. Maurer  
(Reg. No. 31,278)  
Attorney for Applicant(s)  
Hoechst Celanese Corporation  
Route #202-206 North/P.O. Box 2500  
Somerville, New Jersey 08876-1258  
(908) 231-4079



Docket No. BDI-1020

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Attorney Docket No.:	BDI-1020
Inventors:	Ryncarz
Serial No.:	Not yet Assigned
Filing Date:	Not yet Assigned
Examiner:	Not Yet Assigned
Group Art Unit:	Not Yet Assigned
Title:	Positive Controls in Polynucleotide Amplification

**BOX SEQUENCE**

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Dear Sirs:

**STATEMENT TO SUPPORT FILING AND SUBMISSION  
IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825**

- ( X ) I hereby state, in accordance with the requirements of 37 C.F.R. § 1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR § 1.821(c) and (e), respectively are the same.
- ( X ) I hereby state that the submission filed in accordance with 37 CFR § 1.821(g) does not include new matter.
- ( ) I hereby state that the submission filed in accordance with 37 CFR § 1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
- ( ) I hereby state that the amendments, made in accordance with 37 CFR § 1.825(a), include in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at page \_\_\_\_\_. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.

08791240-01097


- ( ) I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR § 1.825(b), is the same as the amended Sequence Listing.
- ( ) I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR § 1.85(d), contains identical data to that originally filed.

Respectfully submitted,



Barbara V. Maurer  
(Reg. No. 31,278)  
Attorney for Applicant  
Hoechst Celanese  
Corporation  
Route #202-206 North  
Somerville, New Jersey 08876  
(908) 231-4079

Date:



260ETD-0426/80